Dr. Collet’s tenure comes at a pivotal moment when non-invasive cardiovascular imaging modalities such as coronary computed tomography angiography (CCTA) are redefining diagnostic paradigms. With his expertise, CRF® aims to harness these advances to improve patient stratification and outcomes in coronary artery disease. His leadership will be integral in bridging the gap between cutting-edge imaging techniques and the nuanced understanding of coronary physiology, fostering an environment where translational science accelerates therapeutic innovation.

The appointment reflects CRF®’s commitment to elevating the scientific rigor and clinical impact of its cardiovascular imaging and physiology programs. Dr. Juan F. Granada, President and CEO of CRF®, emphasized the transformative potential of Dr. Collet’s arrival, highlighting how his knowledge of coronary CT technology embodies the future of cardiovascular diagnostics. Dr. Granada underlined the strategic importance of embedding advanced imaging within CRF®’s multifaceted approach to cardiovascular care and research.

At the core of Dr. Collet’s vision is the expansion of CRF®’s imaging portfolio through the introduction of novel coronary and endovascular services. Alexandra Popma, MD, Executive Director of CRF®’s Clinical Trials Center, expressed enthusiasm for the innovative trajectory Dr. Collet will foster. She noted that his combined clinical acumen and scientific leadership are essential for refining imaging capabilities, which are critical for elucidating cardiovascular pathophysiology and enhancing precision medicine strategies.

Dr. Collet’s distinguished background encompasses more than 300 peer-reviewed publications, reflecting his prolific contribution to interventional cardiology, vascular imaging, and translational research. His recent leadership at the Cardiovascular Center OLV Aalst’s catheterization laboratory in Belgium underscored his expertise in applying physiological measurements alongside imaging data to complex coronary artery disease cases. This dual focus on anatomy and physiology is pivotal in advancing personalized treatment approaches.

His educational journey spans multiple continents and specialties, with foundational medical training at the Dante Pazzanese Institute of Cardiology in São Paulo and advanced postgraduate study in cardiac computed tomography angiography at Holy Cross Hospital in Florida. Crucially, Dr. Collet earned a PhD from the University of Amsterdam with research concentrated on the integration of coronary imaging and physiology—a specialty that positions him uniquely to spearhead translational efforts at CRF®.

The integration of coronary CT imaging with physiological measurements like fractional flow reserve (FFR) represents a transformational approach in cardiovascular medicine. By combining anatomical and functional assessments, clinicians can more precisely stratify risk and tailor interventional strategies. Dr. Collet’s expertise in deploying these hybrid modalities will likely accelerate the adoption of evidence-based, minimally invasive diagnostics that reduce procedural complications and improve long-term outcomes.

Innovation within CRF® under Dr. Collet’s direction will not be limited to technological deployment. He advocates for the creation of multidisciplinary platforms that unify translational science, biomedical engineering, and clinical practice. Such platforms are designed to facilitate rapid bench-to-bedside translation of discoveries, integrating artificial intelligence and machine learning to further refine diagnostic precision and predict therapeutic responses.

Dr. Collet’s vision extends to education, ensuring that CRF® remains at the forefront of training healthcare professionals globally. By enhancing curriculum content with the latest imaging and physiology techniques, CRF® aims to cultivate a new generation of cardiologists skilled in interpreting complex diagnostic data and implementing personalized therapies. This educational mission aligns with the foundation’s broader goal of disseminating evidence-based knowledge to improve survival rates and quality of life for patients worldwide.

The synergy between imaging modalities, physiological assessments, and translational therapeutics represents a frontier with immense potential. By uniting these disciplines under Dr. Collet’s leadership, CRF® endeavours to catalyze innovation, foster collaborative research networks, and promote clinical trials that validate new diagnostic and therapeutic strategies. These efforts will ultimately lead to more nuanced and effective management of cardiovascular diseases, including ischemic heart disease and heart failure.

Dr. Collet’s appointment signals a commitment to advancing the cardiovascular field through integrative approaches that leverage technology and clinical insight. As cardiovascular diseases remain a leading cause of morbidity and mortality globally, breakthroughs in imaging and physiology are essential to meet the challenges of early detection and treatment optimization. CRF®’s leadership in this arena is expected to have far-reaching impact, influencing practice guidelines and elevating standards of care worldwide.

Expressing his enthusiasm, Dr. Collet stated, “Joining CRF® allows me to contribute to a mission grounded in innovation, science, and education. We stand on the cusp of transformative change in cardiovascular medicine, driven by imaging and translational research. Together, we will expand our coronary and endovascular services, develop new diagnostic platforms, and foster personalized care paradigms that improve patient outcomes on a global scale.” His appointment exemplifies CRF®’s forward-looking strategy to harness expertise and technology for the betterment of cardiovascular health internationally.

Subject of Research: Cardiovascular Imaging, Coronary CT Angiography, and Translational Therapeutics in Coronary Artery Disease

Article Title: Renowned Cardiologist Dr. Carlos Collet Appointed Director of Cardiovascular Imaging and Translational Therapeutics at CRF®

News Publication Date: September 9, 2025

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/028f5ce5-58eb-4308-9387-cd55c33520c5/Rendition/low-res/Content/Public

Image Credits: Cardiovascular Research Foundation

Keywords: Cardiovascular Imaging, Coronary CT Angiography, Interventional Cardiology, Translational Therapeutics, Coronary Physiology, Cardiovascular Disease, Cardiovascular Research Foundation, Personalized Cardiovascular Care, Coronary Artery Disease, Cardiac Computed Tomography, Fractional Flow Reserve, Cardiovascular Innovation

Traditionally, HFpEF was linked primarily to elevated blood pressure, which was thought to induce stiffness in the heart muscle. However, emerging data challenge this perspective, indicating that nearly all HFpEF patients harbor significant accumulations of internal fat surrounding vital organs, including the heart itself. Unlike subcutaneous fat, this visceral and pericardial adiposity engages in complex biochemical signaling that profoundly impacts cardiac structure and function. The Adipokine Hypothesis explicates these interactions and their pathophysiological consequences.

Adipokines are bioactive signaling molecules secreted by adipose tissue; in physiologic states, they maintain homeostasis by downregulating inflammation, supporting vascular and renal health, and modulating fluid balance. This harmonious crosstalk ensures cardiovascular resilience. In contrast, the presence of excessive internal fat tissue invokes a pathological transformation in adipokine secretion profiles. The altered adipokines potentiate inflammation, oxidative stress, and fibrotic remodeling within the myocardium, fostering the hallmark stiffness observed in HFpEF. Thus, the heart is not merely passively affected by extrinsic pressure but is actively injured via maladaptive molecular signals emanating from surrounding fat depots.

Experimental pharmacological studies corroborate this mechanistic framework. Therapeutic agents that target fat tissue biology—rather than the myocardium itself—have demonstrated efficacy in alleviating HFpEF phenotypes. These drugs modulate adipokine secretion, attenuate cardiac fibrosis, and improve diastolic function, thus validating the hypothesis that fat is a central driver rather than an innocent bystander. Notably, several such agents already bear FDA approval for HFpEF treatment but remain underutilized in clinical practice. Additionally, glucagon-like peptide 1 (GLP-1) receptor agonists, including semaglutide and tirzepatide, have shown promising adipokine-modulating effects, potentially offering another therapeutic avenue.

Measuring fat-related risk factors also demands refinement. Body mass index (BMI), a conventional indicator of obesity, fails to distinguish between adiposity and lean mass, leading to diagnostic ambiguity. Instead, waist-to-height ratio has emerged as a more reliable metric for identifying individuals with excessive internal fat accumulation. A ratio exceeding 0.5 signals heightened risk, and most patients with HFpEF have ratios surpassing 0.6. This simple anthropometric measure enables clinicians to screen more effectively for HFpEF risk and initiate timely evaluation for symptomatic patients frequently misattributing exertional breathlessness to mere obesity.

The clinical implications extend beyond diagnostics. Early recognition of aberrant adipokine signaling and its cardiac consequences enables targeted interventions. Patients with elevated waist-to-height ratios presenting with dyspnea on exertion should undergo thorough HFpEF assessment. This approach can prevent underdiagnosis and mismanagement, offering opportunities to deploy therapeutics that reverse fat-mediated cardiac injury and improve quality of life.

The Adipokine Hypothesis echoes the transformative impact of Packer’s earlier work on heart failure with reduced ejection fraction (HFrEF). Over three decades ago, he introduced the neurohormonal hypothesis, redefining heart failure pathophysiology and guiding new therapeutic developments. The current hypothesis similarly reshapes the conceptual landscape of HFpEF, a condition historically marked by limited therapeutic options and prognostic ambiguity.

To complement this foundational paper, two additional studies published concurrently in JACC: Heart Failure delve into related molecular mechanisms. One explores the influence of eicosanoid adipokines in orchestrating inflammation within the HFpEF milieu, while the other investigates adipoexosomal microRNAs as novel regulators of cardiac fibrosis and remodeling. Together, these investigations provide a multi-dimensional understanding of how fat tissue reprogramming disrupts cardiac homeostasis at both systemic and molecular levels.

The Adipokine Hypothesis galvanizes a shift toward precision cardiovascular medicine, where interventions focus on modulating the biochemistry of adipose tissue rather than solely attempting to palliate heart muscle dysfunction. This paradigm shift holds promise for addressing the vast and growing global burden of HFpEF, a syndrome presently impacting nearly 4 million Americans and over 32 million individuals worldwide. As obesity rates climb, untangling fat’s complex role in cardiovascular disease becomes increasingly vital.

In summary, the Adipokine Hypothesis elucidates a previously underappreciated etiological pathway in HFpEF: the transformation of internal fat tissue from a protective to a pathogenic entity. By secreting a deleterious array of adipokines, excess adiposity instigates cardiac inflammation and fibrosis, leading to impaired relaxation and heart failure symptoms. Importantly, targeted pharmacotherapy that restores adipose tissue homeostasis provides a compelling therapeutic strategy. This new model not only enhances diagnostic accuracy via waist-to-height ratio assessment but also empowers clinicians to apply existing and emerging therapies tailored to the root cause rather than just the cardiac consequence of HFpEF.

With HFpEF’s complexity unraveled through the prism of adipokine biology, this hypothesis opens avenues for innovative clinical trials, multidisciplinary research, and ultimately improved patient outcomes. The field now stands at the cusp of a transformative era that reconceptualizes fat as an active cardiac player rather than a passive risk factor—ushering in hope for millions awaiting effective treatments for this pervasive form of heart failure.

Subject of Research: Heart failure with preserved ejection fraction (HFpEF) and the role of internal fat tissue and adipokines.

Article Title: The Adipokine Hypothesis: A Novel Framework Explaining the Role of Internal Fat Tissue in HFpEF.

News Publication Date: Not explicitly stated; inferred from context as around ESC Congress 2025.

Web References:

• https://www.ACC.org
• https://www.jacc.org

Keywords: Cardiovascular disease, Heart failure with preserved ejection fraction, Adipokines, Internal fat tissue, Waist-to-height ratio, GLP-1 receptor agonists, Cardiac inflammation, Cardiac fibrosis, Obesity, Metabolic disorders

As cardiology continues to evolve, it has reached a complexity that necessitates a specialized certification board. Cardiovascular medicine has undergone considerable transformations over the years, giving rise to specialized fields within cardiology, such as heart failure, electrophysiology, and interventional cardiology, each with their unique sets of knowledge, skills, and practice requirements. These distinct segments underscore the necessity for a dedicated board that can address the specificities of cardiology, rather than subsuming these nuances under the broader umbrella of internal medicine.

The ABMS’s stance does not align with the increasing recognition of cardiology as its own specialty with distinct educational pathways. The emergence of advanced cardiological technologies and interventions necessitates not only a deeper level of knowledge but also a sustained commitment to ongoing education among practitioners. Thus, the argument for an independent board is built on the foundation of improving patient outcomes through specialized training and continuous professional development.

Moreover, the ABCVM put forth a robust application underscoring its commitment to the new standards of continuing certification set forth by the ABMS. These standards emphasize a pivot from punitive approaches to assessments toward more supportive measures that enhance professional development. The rejection of such a forward-thinking initiative calls into question the ABMS’s commitment to adapting to the evolving landscape of medical practice, particularly in cardiology.

Financially, the ABCVM had laid out a comprehensive plan that not only met but exceeded the financial expectations set by the ABMS for establishing a new board. This financial backing was not merely a formality; it was a reflection of the extensive professional support resonating from various organizations committed to advancing the field of cardiology. The collaboration of significant stakeholders in the American Heart Association, American College of Cardiology, and other professional societies demonstrated a united front advocating for the establishment of the ABCVM.

The community’s discontent signals a broader issue beyond corporate proceedings; it raises questions about how regulatory bodies perceive the evolving needs of healthcare providers and, by extension, patients. As the medical landscape continues to shift, the demand for responsive and specialized forms of governance in medical practice becomes paramount. The current approach to physician competency and assessment requires rethought to align with modern practices and technologies that are reshaping patient care.

While the ABCVM Board of Directors contemplates its next steps, it anticipates that there will be productive discourse following the ABMS’s decision. Constructive feedback from within the cardiovascular community is expected to influence future interactions and decisions regarding certification and competency standards. This instance emphasizes the necessity for ongoing dialogue between professional societies and regulatory bodies to ultimately foster a healthcare system that prioritizes excellence and patient care.

The discourse surrounding the ABCVM’s application reflects a pivotal moment not just for cardiology but for all medical specialties navigating the complexities of specialization. The insistence on creating an independent board illustrates the ongoing quest for professional recognition and validation within medical fields that are rapidly transforming. It is vital for governance bodies to champion innovations in practice that reflect the evolving expertise of medical professionals.

In light of the current climate in cardiology and healthcare at large, this disappointment serves as a rallying point for advocates seeking change. The cardiovascular community is urged to unify and reaffirm the call for an independent certifying board that recognizes the legitimate need for specialized training and assessment. Such a move is not merely about professional autonomy; it represents a commitment to fostering excellence in patient care through dedicated, relevant, and advanced training mechanisms.

Ultimately, the rejection of the ABCVM is a call to action. It brings forth an opportunity for stakeholders to engage actively with regulatory bodies and reshape how board certifications are viewed and administered in medicine. As medical specialties progress and become more complex, the structures that govern them must also evolve, ensuring that they reflect the realities of modern medical practice and adequately serve the interests of both healthcare professionals and patients.

As members of the cardiovascular community reflect on ABMS’s decision, they stand at a crossroads. It is essential that they channel their collective expertise and advocacy into constructive initiatives that can pave the way for future advancements in the field. A potential path forward remains open, emphasizing that the struggle for recognition within medical specialties is not only about professional credibility but also about enhancing the quality of healthcare delivered to patients.

The journey towards establishing a separate certifying body for cardiology continues, fueled by the conviction that cardiovascular health deserves dedicated representation among medical certifications. In so doing, the ABCVM and its supporters remain steadfast in their resolve to ensure that the competency and quality of care provided to patients remain at the forefront of the cardiology landscape.

As this conversation evolves, the cardiovascular community is called to engage actively, foster partnerships, and advocate tirelessly for the acknowledgment and structural support warranted by the distinct domain of cardiovascular medicine. The road ahead may be fraught with challenges, yet the mission remains clear: pursuing excellence and innovation in cardiovascular care for the benefit of patients and the healthcare system as a whole.

Subject of Research: Evolution of Cardiovascular Medicine and Specialty Certification
Article Title: The Struggle for Recognition: Cardiologists Advocate for Independent Certification
News Publication Date: October 24, 2023
Web References: N/A
References: N/A
Image Credits: N/A
Keywords: cardiology, medical specialties, American Board of Medical Specialties, certification, American Board of Cardiovascular Medicine, healthcare quality, continuing certification.

Dr. Robert Rosenson, a distinguished Professor of Medicine (Cardiology) at Mount Sinai and the lead author of the study, emphasized the groundbreaking nature of their research. The analysis of the trial demonstrated that higher doses of olpasiran caused reductions in Lp(a) levels by over 95 percent in participants suffering from atherosclerotic cardiovascular disease. These formidable results, published in the prestigious journal JAMA Cardiology on February 12, 2025, signal a possible paradigm shift in how we approach cardiovascular health.

Lipoprotein(a) is particularly notorious in cardiovascular research. Considered a major facilitator in the transport of oxidized phospholipids, Lp(a) is linked to inflammation and the progression of atherosclerosis, which can lead to serious vascular complications. This trial, as it turns out, was the first to explore the relationship between oxidized phospholipids present on Lp(a) and inflammatory mediators in a clinical setting. The intricate biological dance between Lp(a) and inflammation unlocked new pathways in understanding cardiovascular disease etiology.

Olpasiran functions as a small interfering RNA, exhibiting a sophisticated mechanism to curtail Lp(a) production. By inducing degradation of apolipoprotein(a) messenger RNA—essentially the blueprint for forming Lp(a)—olpasiran effectively diminishes one of the significant players in the lipid profile of at-risk patients. This process underscores olpasiran’s potential therapeutic efficacy as a targeted intervention against cardiovascular disease, especially in those with elevated Lp(a) levels.

What makes olpasiran particularly noteworthy in clinical practice is its results from the randomized phase 2 clinical trial known as OCEAN(a)-DOSE. This trial involved 282 patients who were not only living with cardiovascular disease but had Lp(a) levels exceeding 150 nmol/L. This threshold is crucial, given that such levels have been associated with heightened risks of clotting and inflammation that can compromise heart health. The study aimed to provide a clearer picture of how olpasiran could alter these risk dynamics and contribute to novel therapeutic strategies.

The results illuminate a compelling narrative for the utility of olpasiran. Participants administered doses of 75 mg or higher every 12 weeks showcased a remarkable 95 percent reduction in Lp(a) when evaluated against a placebo group over a 36-week period. In stark contrast, the placebo cohort experienced a 3.6 percent uptick in Lp(a) levels. This disparity reinforces the potential of RNA inhibitors as transformative tools in the management of cardiovascular diseases linked to high Lp(a) levels.

Beyond decreasing Lp(a), the research team noted that olpasiran also lowered levels of oxidized phospholipids associated with apolipoprotein B—an essential lipid transport protein implicated in cardiovascular disease. However, intriguingly, the study did not observe significant effects on the secretion of proinflammatory cytokines such as interleukin-6 or C-reactive protein in comparison to those receiving the placebo. This nuanced understanding is vital, as it directs future research efforts toward elucidating the comprehensive impacts of olpasiran on not just one but multiple fronts of cardiovascular pathology.

Dr. Rosenson articulated the need for further investigations that delve into the mechanisms through which Lp(a) contributes to cardiovascular risk. By challenging existing paradigms, his team’s work sets the stage for more personalized approaches in patient selection for future trials, particularly those exploring the anti-inflammatory potential of RNA inhibitors in combating cardiovascular diseases. The scientific community’s collective actions now must leverage this foundational work to tease apart the complexities inherent in lipid-mediated atherosclerosis.

The trial’s sophisticated structure and significant outcomes echo a shifting paradigm in therapeutic development for cardiovascular ailments. The OCEAN(a)-DOSE trial was expertly orchestrated under the auspices of the TIMI Study Group and received sponsorship from Amgen, a crucial relationship that underscores the importance of collaboration between academia and industry in advancing healthcare solutions. As the medical fraternity anticipates phase 3 trials for olpasiran, hope grows for a future where innovative therapies reshape the landscape of cardiovascular disease management.

Mount Sinai’s continuous commitment to excellence in cardiology is underscored by its ranking as a leading institution for heart health, especially in light of its innovative research and clinical advancements. As healthcare systems grapple with escalating cardiovascular disease rates, findings like those from the olpasiran trial point to a crucial direction for future therapeutic protocols. Acknowledging the complexity of cardiovascular health, the insights garnered from this study lend themselves to a broader discourse on the imperative of personalized medicine in the fight against cardiovascular disease.

As the scientific community, healthcare professionals, and patients alike await the next steps, olpasiran stands as a beacon of hope in a field that urgently requires transformative approaches. This RNA inhibitor’s potential for significantly altering the risk landscape associated with Lp(a) heralds a new era of cardiovascular disease management—one where innovation meets patient-oriented care to revolutionize health outcomes globally.

Researchers, clinicians, and patients must remain vigilant as they further navigate this promising frontier in cardiovascular health, ensuring that advancements like olpasiran not only enter clinical practice but also become standard components of comprehensive care strategies aimed at reducing cardiovascular morbidity and mortality.

Subject of Research: People
Article Title: Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers
News Publication Date: 12-Feb-2025
Web References:
References:
Image Credits: Credit: Mount Sinai Health System

Keywords: Cardiovascular Health, Lipoprotein(a), RNA Inhibitor, Olpasiran, Atherosclerosis, Inflammation, Clinical Trials, Pharmacology, Personalized Medicine, Heart Disease, Oxidized Phospholipids, Apolipoprotein B.